VRTX
VRTX
NASDAQ · Biotechnology

Vertex Pharmaceuticals Inc

S&P 500 Nasdaq 100 Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks
$436.95
-13.46 (-2.99%)
As of May 16, 1:01 AM ET ·
VRTX News3 articles
Forgent Power Soars on Record Orders, AI Data Center Demand Drives Growth
Forgent Power Solutions raised its FY2026 revenue forecast after record Q3 bookings of $867 million, signaling robust AI data center demand. Shares jumped in premarket trading.
Earnings
Vertex Shares Slide on Updated Safety Warnings for CF Drugs
Vertex Pharmaceuticals shares declined 4.6% to $433.07 following updated U.S. safety labels for its cystic fibrosis drugs citing serious neuropsychiatric events. The company maintains its 2026 revenue outlook remains heavily dependent on CF treatments.
Regulation
Vertex Shares Surge on Analyst Upgrade, Pipeline Expansion in Focus
Vertex Pharmaceuticals shares climbed 5.7% following an upgrade from Oppenheimer, driven by its 2026 revenue outlook and expanding pipeline in gene-editing, pain, and kidney therapies.
Analysis